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Abstract
Background: Although public health guidelines have implications for resource allocation, these issues were not explicitly
considered in previous WHO pandemic preparedness and response guidance. In order to ensure a thorough and informed
revision of this guidance following the H1N1 2009 pandemic, a systematic review of published and unpublished economic
evaluations of preparedness strategies and interventions against influenza pandemics was conducted.
Methods: The search was performed in September 2011 using 10 electronic databases, 2 internet search engines, reference
list screening, cited reference searching, and direct communication with relevant authors. Full and partial economic
evaluations considering both costs and outcomes were included. Conversely, reviews, editorials, and studies on economic
impact or complications were excluded. Studies were selected by 2 independent reviewers.
Results: 44 studies were included. Although most complied with the cost effectiveness guidelines, the quality of evidence was
limited. However, the data sources used were of higher quality in economic evaluations conducted after the 2009 H1N1
pandemic. Vaccination and drug regimens were varied. Pharmaceutical plus non-pharmaceutical interventions are
r e l a t i v e l yc o s te f f e c t i v ei nc o m p a r i s o nt ov a c c i n e sa n d / o ra n t i v irals alone. Pharmaceutical interventions vary from cost saving
to high cost effectiveness ratios. According to ceiling thresholds (Gross National Income per capita), the reduction of non-
essential contactsand the use of pharmaceuticalprophylaxis plusthe closure of schools are amongst the cost effective strategies
for all countries. However, quarantine for household contacts is not cost effective even for low and middle income countries.
Conclusion: The available evidence is generally inconclusive regarding the cost effectiveness of preparedness strategies and
interventions against influenza pandemics. Studies on their effectiveness and cost effectiveness should be readily
implemented in forthcoming events that also involve the developing world. Guidelines for assessing the impact of disease
and interventions should be drawn up to facilitate these studies.
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Introduction
When a new subtype of influenza A virus which is infectious to
humans gains human-to-human transmissibility efficiently enough
to cause community level outbreaks, this virus is said to have
pandemic potential. If this new subtype spreads globally causing
disease and deaths, it becomes pandemic. Since the 16th century,
influenza pandemics have occurred at intervals ranging between
10–50 years, creating varying levels of impact on societies. [1] In
March 2009, a new subtype of influenza A H1N1 virus was
identified in Mexico and the United States. It spread to all
continents in less than nine weeks becoming the first pandemic of
the 21st century. Children, young adults, pregnant women, and
those with chronic illnesses were disproportionately affected and
constituted the majority of the hospitalization cases. The estimated
case fatality rate was 0.15–0.25%, with most deaths in middle-
aged adults with underlying diseases. [2] Although concrete
evidence on the macroeconomic consequences of the 2009 H1N1
pandemic have not yet been revealed, previous studies estimated
the potential reduction of labor productivity and consumption
demand, with results showing an approximately 2–5% decrease in
annual gross product. [3,4]
The World Health Organization (WHO) published pandemic
preparedness and response guidance in 1999 with two revisions:
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summarize the recommended WHO and national actions against
pandemic influenza according to recognized pandemic phases. For
some recommendations, evidence is limited to observations or
epidemiological models. In some cases, inferences are drawn from
other respiratory infectious diseases, such as seasonal influenza or
severe acute respiratory syndrome. With a view to incorporating
important experience and evidence acquired during the H1N1
2009 pandemic, the WHO will revise its pandemic preparedness
guidelines. Including cost effectiveness evidence in the revision
process will strengthen the guidance by providing a framework to
prioritize the allocation of limited resources in impending, high
risk times.
The aim of this paper is to systematically review published and
unpublished economic evaluations of interventions to control and
prevent human influenza pandemics. Funded by the WHO, this
study describes and assesses the identified studies and determines
patterns in cost utility ratios. The findings are expected to
contribute to the revision of the WHO guidance on pandemic
influenza, potentially support policymakers to make informed
decisions on allocating resources effectively, and identify gaps for
future research.
Methods
Data Sources and Searches
On 22 September 2011, a systematic search was performed in
MEDLINE (via PubMed, 1950–22.09.2011), as well as in the
specialist databases NHS EED (via CRD, 1992–22.09.2011),
HEED (via Wiley Online Library, 1992–08.2011), CEA Registry
(1976–2010), EURONHEED (via INSERM, 1980–2010), HTA
(via CRD, 1988–22.09.2011), Health Evidence Network (HEN)
(via WHO/Europe, on 22.09.2011), EconLit (via Ovid, 1969–
08.2011), and Research Papers in Economics (RePEc) (via Ideas,
1990–22.09.2011). Since it was expected that a majority of
pharmaceutical interventions would be identified from the above-
mentioned databases, a search through the Social Science Citation
Index (SSCI) (via ISI Web of Knowledge, 1970–22.09.2011),
which is more focused on non-pharmaceutical issues and also
covers conference proceedings, was also performed.
To retrieve additional grey literature reports and conference
proceedings, the search was expanded by using the generic search
engine Google (www.google.co.uk, on 06.10.2010/22.09.2011),
and the science specific search engine Scirus (www.scirus.com,
2009–22.09.2011). Furthermore, reference lists of relevant publi-
cations were screened. and cited reference searching of the first
economic evaluation on this topic [5] was also performed using
Web of Science (via ISI Web of Knowledge, 1970–22.09.2011).
Additional reports were obtained through correspondence be-
tween one reviewer (RPV) and authors of eligible studies and
conference abstracts.
The search strategies used controlled vocabulary thesaurus
terms, whenever available, and relevant free text terms, including
‘pandemic’, ‘H1N1’, ‘influenza’, ‘cost benefit’, ‘cost(s)’, ‘cost
effective’ and ‘economic(s)’, in different combinations. Free text
terms in other languages were also employed when appropriate.
Search strategies applied to electronic data sources, and outputs
are shown in Table S1 and S2.
Study Selection
All identified abstracts were reviewed by two independent
reviewers from a review team (AM, KW, NP, RPV and SK).
Discrepancies were resolved by a third reviewer (YT). The papers
wereincludedintheanalysisiftheymetthecriteriashowninTable1.
Data Extraction and Quality Assessment
A standardized data extraction form was devised. The articles
were grouped according to type of evaluation as follows: i) a cost
minimization analysis if they compared costs of different
interventions with evidence of equal effectiveness; ii) a cost benefit
analysis (CBA) if they measured health outcomes in monetary
units; iii) a cost effectiveness analysis (CEA) if they expressed health
outcomes in natural units, e.g., cases averted, hospitalizations
averted, or deaths averted; and iv) a cost utility analysis (CUA) if
they presented health outcomes in common units, e.g., quality
adjusted life years (QALYs) or disability adjusted life years
(DALYs).
The studies were appraised in two different ways for quality
assessment purposes following approaches employed by Teera-
wattananon et al. [6] First, they were assessed according to specific
methodological and reporting practices for economic evaluation
studies such as expression of perspective used, relationship
between time horizon and discounting, reporting of incremental
cost effectiveness ratios (ICERs), performing uncertainty analysis,
and declaration of funding support. Second, studies were assessed
according to the quality of evidence used, since it is widely
recognized that the credibility of economic evaluations depends
not only on the appropriateness of the methods employed but also
on the input evidence. Several types of evidence are evaluated
according to their level of quality: i) clinical effect sizes; ii) adverse
events and complications; iii) baseline clinical data; iv) resource
use; v) costs; and vi) utilities (only applicable to cost utility
analyses). The data sources of each component are ranked from
one to six in descending order. Rank 1 is given if parameters are
derived from the most appropriate data sources. [6,7] (For detailed
information about ranking consult Table S3; for technical terms
used in the data extraction, the definitions given by the HTA
Glossary were used: http://htaglossary.net).
Data Synthesis and Analysis
This review compared the value for money of different
interventions for the prevention and control of influenza
pandemics in comparison with ‘no intervention’; however, the
evaluations were conducted in different settings and timeframes.
This study converted cost effectiveness ratios into a common
currency and utility unit. Costs in international dollars (I$), at 2011
values, were calculated using national gross domestic product
deflator values and implied purchasing power parity conversion
rates from the International Monetary Fund (http://www.imf.
org/external/ns/cs.aspx?id=28). In addition, exchange rates
obtained from the OANDA website (http://www.oanda.com/
currency/historical-rates) were applied when cost outcomes were
reported in foreign currencies rather than in local equivalents.
Because of the lack of explicit and implicit thresholds for most
countries to determine which interventions are cost effective, the
World Bank thresholds for classifying countries into low income,
lower middle income, upper middle income, and high income
countries according to 2010 Gross National Income (GNI) per
capita were used as maximum ceiling thresholds. [8] In other
words, the interventions that spent fewer resources than the upper
bound of GNI per capita given by the World Bank in order to gain
one QALY or save one DALY represent good value for money.
Results
Review profile
The search in the electronic databases identified a total of 677
records. In addition, 510 records were identified through internet
search engines. There were 98 records that met the inclusion
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included in the final analysis. These studies were excluded because
they were reviews (14), were not economic evaluations (9), focused
on seasonal influenza (6), focused on the impact of influenza (7),
had no full text available for some conference abstracts (9), were
not in the eligible languages (1), or did not report both the costs
and outcomes of interventions (10). In addition, eight full text
papers were identified from correspondence with authors of
eligible papers, cited reference searching, and reference list
screening, of which six were excluded as they studied the impact
of disease (2) or were not economic evaluations (4). Finally, 44
studies were considered in our analysis (Figure 1).
Description of results
The majority of studies adopted CEA and CUA approaches: 14
CEA, 16 CUA, 2 CEA and CBA combined, and 1 CEA and CUA
combined. Six studies reported CBA results and five partial
economic evaluations. Figure 2 illustrates the relationships among
study setting, year of study, and year of publication. More than
half of the studies (n=23) were conducted in 2009 and 2010 after
the H1N1 pandemic event. 14 studies assessed the value for money
of interventions in the United States, followed by Canada (n=5),
the United Kingdom and Singapore (n=3, each), Australia, the
Netherlands, and France (n=2, each), and another five countries
with one study each. There were three studies conducted for
Table 1. Inclusion and exclusion criteria employed in the abstract selection process.
Inclusion Criteria Exclusion Criteria
NOriginal economic evaluations considering prevention or control of the 2009
human influenza pandemic or other potential human influenza pandemics
NPartial economic evaluations if both costs and outcomes of one intervention,
either pharmaceutical or non-pharmaceutical, were considered
NFull economic evaluations if costs and outcomes of more than one
pharmaceutical or non-pharmaceutical interventions were considered
NReviews or editorials of original studies
NStudies not including both costs and outcomes of interventions
NStudies of economic impact of influenza pandemics per se
NEconomic evaluations of interventions related to influenza pandemic complications
NNo provision of English, Spanish, German, Thai and Dutch full texts (for which the
review team possessed language translation ability)
doi:10.1371/journal.pone.0030333.t001
Figure 1. Flow of study selection. * Records duplicated inside an individual database or internet search results list.
doi:10.1371/journal.pone.0030333.g001
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European countries [9] while another covered up to ten countries
in diverse income groups. [10] The characteristics of the studies
included in the analysis [11–51] are summarized in Table S4.
Modified from the WHO and the World Bank’s classification
for the containment and mitigation of influenza pandemics,
[52,53] Table 2 depicts that vaccination (n=22) and antiviral
drugs (n=25) were commonly evaluated for both target groups
(specific groups, such as high risk or priority populations) and the
general population. Notably, no economic evaluation assessed the
economic value of public hygiene and disinfection measures.
There were considerable discrepancies among drug and vaccine
regimens considered in the economic evaluations. Although the
majority (n=18) assessed oseltamivir, they used different dosages
and durations for prophylaxis. For example, some authors [51]
used oseltamivir 75 mg once daily for 10 days for prophylaxis in
young adults in the US, whilst others [13] used the same dosage of
oseltamivir for 50 days of prophylaxis among the Israeli general
population. The number of vaccine doses ranged from one to
three, with the vast majority of papers not clearly specifying the
duration of protection (Table S5).
Table 3 shows the extent to which the 44 reviewed papers
complied with standards for conducting and reporting economic
evaluations. A relatively high proportion of studies described the
study perspective(s), selection of comparators, using discounting
for costs and/or outcomes for studies with time horizon longer
than one year, and performing uncertainty analyses. However,
only approximately 70% of the studies calculated and reported
ICERs, and disclosed funding sources.
Twenty eight studies adopted a societal viewpoint in the
analysis. Seven studies employed a healthcare provider’s perspec-
tive and four studies adopted a healthcare system’s perspective.
Regarding financial support, 18 studies were supported by
domestic public funders, 4 by the for-profit private sector, 1 by
public private co-funding, 3 by not-for-profit domestic and
international co-funding and 1 by an intergovernmental organi-
zation. 13 studies did not properly declare the source of funding.
All of the studies except two were model based, adopting either
dynamic or static approaches, whereas one study compared both
approaches. [36] Only one paper did not clearly state the
approach used. [37] Time horizons (the time window during
which patients were followed and their resource use and health/
cost outcomes measured) varied largely across studies, ranging
from one month to a lifetime. 16 studies (36.4%) did not clearly
state the time horizon employed (Table S4).
Table 4 compares the quality of evidence used for economic
evaluations conducted before and after the 2009 H1N1 pandemic.
It illustrates the poor quality of data used for baseline clinical data,
estimating adverse events and complications of interventions,
resource use, and utilities for the studies conducted before 2009.
More than half of this information was from non-analytic studies
(e.g., case reports or case series), expert opinions, and unsourced
information. A significant improvement was observed for
economic evaluations conducted after the 2009 event. For these
studies, a majority of baseline clinical data was obtained from case
series or the analyses of reliable administrative databases from the
setting of interest. Almost half of these studies employed resource
use information from reliable administrative data sets from the
setting of interest and also over half of the utilities were derived
from direct or indirect utility assessment rather than from
unknown sources or expert opinion. Nevertheless, there was not
much difference in the quality of clinical effect size parameters
between the before and after studies. This may be explained by the
fact that the most appropriate clinical effect size source is the
Figure 2. Study setting by year of study and year of publication.
doi:10.1371/journal.pone.0030333.g002
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the availability of this type of study.
Incremental cost effectiveness ratios (ICERs)
Figure 3 compares the cost per QALY of each intervention as
well as before and after the 2009 H1N1 pandemic. Evidence
suggests that providing interventions either to the general
population or only to target groups does not yield a significant
influence on ICERs.
The combination of pharmaceutical and non-pharmaceutical
interventions is relatively cost effective compared to providing
vaccines and/or antiviral drugs. For pharmaceutical interventions,
ICERs can vary largely, from cost saving to very high values (.I$
1,000,000 per QALY). According to the predefined ceiling
thresholds, ‘social distancing’ (a strategy in which non-school,
non-work and non-household personal contacts are reduced [40]),
antiviral prophylaxis for the general population plus the closure of
schools, vaccination for the general population plus the closure of
schools, and antiviral prophylaxis for household contacts plus the
closure of schools are amongst the cost effective strategies for all
low, middle and high income countries because their ICERs are
well below the maximum ceiling threshold for low income
countries (lowest dot line). (Of course, the interventions that are
cost effective for low income countries should also be cost effective
for countries with higher incomes). Quarantine for household
contacts seems unlikely to be cost effective even for low and middle
income countries because the ICER is well above the maximum
ceiling threshold for upper middle income countries. (However,
this interpretation cannot apply to high income countries because
it depends on their GNI per capita). Disappointingly, our findings
suggest that most economic evaluations conducted after the 2009
H1N1 pandemic focus on different interventions compared to
studies carried out before the 2009 event. In a few studies that
cover the same interventions, the results do not differ considerably.
There are four important types of parameters in the uncertainty
analyses found in our review (Table S6). These are epidemiological
parameters and those related to natural disease progression
(infectivity, e.g., attack rate or reproduction number; probability
of pandemic; pandemic duration; disease severity, e.g., case fatality
or probability of developing complications), those related to the
intervention (efficacy, coverage, stockpiling capacity, timing of the
intervention), resource use and cost parameters (healthcare costs,
resources consumed, value of life, cost of intervention), and others
(utility and discounting rate). There was no study that systemat-
ically analyzed the relative importance of the parameters. Since all
studies purposively selected parameters for uncertainty analysis,
we cannot make a firm conclusion on which parameters are
important for determining the value for money of pandemic
influenza preparedness strategies and interventions.
Due to the importance of contact patterns in the outcomes of
dynamic models, we also reviewed the mode in which populations
interact. Consideration of contact patterns is especially important
in modeling non-pharmaceutical interventions (e.g. social distanc-
ing), because the effectiveness of these interventions is highly
dependent on how the population interacts or behaves in the
initial phase of the pandemic. [35] It is noteworthy that a number
of reviewed papers do not provide detailed information about
Table 2. Classification of studies by types of interventions, modified from the WHO and World Bank’s taxonomy [52,53].
Community National International
Interventions
* Targeted Broad based
Ex-
ante Ex-post Ex-ante Ex-post Ex-ante Ex-post
Ex-
ante
Ex-
post
Quarantine [40]
Travel restriction [22] (22)
Public Communica-
tions & Advisories
[18] [51]
Social distancing [18] [16,24,38] [26,45] [11]
Public Hygiene and
disinfection
Personal protective
equipment
[18] [50]
Vaccination [14,20,33,41] [9,21,42,51] [5,17,20,26,33,37,39,45] [9,11,15,21,25,26,28,30,44,46,49]
Antiviral Drug [13,20,27,32,41,47,48] [12,19,23–25,31] [13,20,26,29,32,35,36,39,43,45,47] [10,11,24,34,49]
{
*Categories highlighted in grey are not relevant.
{Traditional Chinese Medicine and Integrative Chinese and Western Medicine in [34]considered antiviral drugs.
Ex-ante=before the 2009 H1N1 pandemic; Ex-post=after the 2009 H1N1 pandemic.
doi:10.1371/journal.pone.0030333.t002
Table 3. Extent to which the studies included met
recommendations for reporting of economic evaluations.
6
Recommendations
Number of studies fulfilling
recommendation
*
Percentage
(%)
Perspective specified 41/44 93
Description of comparator(s) 43/44 98
Used discounting for costs
and/or outcomes
if study period was .1 year
15/17 88
Calculated and reported ICER 30/42 71
Performed uncertainty analysis 38/44 86
Disclosed funding sources 31/44 70
*Number of studies in which the recommendation is applicable.
ICER=Incremental cost effectiveness ratio.
doi:10.1371/journal.pone.0030333.t003
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to other epidemiological studies. In this regard, we reviewed the
relevant sources and found that the quality of evidence used ranges
from assumption [51] to data from a large study conducted in the
European Union. [9,12,39,48,49] Only one study conducted after
the 2009 H1N1 pandemic appears to employ real data in areas
affected by the pandemic to construct a social network. [24]
In general, all epidemic models have an underlying network of
mixing patterns, even though this network may not be explicit.
Some compartmental models included in this review do not allow
for variability (i.e., assuming that communities are homogenous or
not taking account of variability derived from age, sex, behavior,
and social and spatial structure) [10,22,25,26,51], although some
include modifications that allow for some level of heterogeneity,
such as age specific mixing patterns. [9,12,35,36,39,48–50] On the
other hand, almost half of the studies included are agent based
models, which appear to reflect the heterogeneity in contact
patterns as occurs in the real world, especially those with a social
network design [11,15,16,21,24,40,43–46] (Table S7).
Discussion
The review identified a fair number of economic evaluations of
preparedness strategies and interventions against influenza pan-
demics, especially after the 2009 H1N1 pandemic, although
evidence remains generally inconclusive with regard to the cost
effectiveness of interventions. This picture does not change when
comparing between studies conducted before and after the
pandemic. The majority of studies (34/44, 77%) focused only on
pharmaceutical interventions such as using vaccines and antiviral
drugs. This may be explained by the nature of non-pharmaceutical
interventions, for which effectiveness and cost effectiveness are
difficult to assess. For instance, it may be unethical to restrict travel
or to introduce public communication and advisory measures for
only specific population groups. There is a lack of standard
protocols for non-pharmaceutical interventions resulting in a large
variability of practice across settings. Also, most of the non-
pharmaceutical interventions are complex, involving multidimen-
sional aspects and difficulties to control confounding factors.
Lastly, in the absence of a pandemic event, it is difficult to
introduce radical public measures (e.g., travel restrictions, school
closure, and quarantine), which hinder opportunities to generate
robust and reliable evidence on effectiveness.
Despite a large number of studies of pharmaceutical interven-
tions, existing evidence on their value for money is unconvincing.
Since different vaccination and drug regimens were examined
across the selected studies, the findings on both the costs and
outcomes of interventions are incomparable, especially from
studies conducted before the pandemic. However, we found
uniform drug regimens for prophylaxis and treatment for studies
conducted after the pandemic. This may be explained by the issue
of some protocols and guidelines by the WHO during the
pandemic.
Regarding methods for economic evaluation, the overall quality
is relatively high. This may be because these studies were
conducted in settings where health economics was well established.
National methodological guidelines for conducting economic
evaluations exist in most of these settings and, therefore, it would
affect the choice of method employed by the researchers. To
improve the comparability of future evaluations, it is important to
introduce internationally accepted methodological guidelines.
Although a WHO guide for standardisation of economic evaluations of
immunization programmes [54] is publicly available, it is applicable
only to vaccination, but not to antiviral drugs and non-
pharmaceutical interventions.
In Figure 3, we present a novel approach to summarize cost
effectiveness evidence across interventions and target populations.
This is useful not only for decision makers in each country, but
Table 4. Quality of evidence used in the 44 economic evaluations included in the review.
Level of
information
Clinical effect
size
[n (%)]
Baseline
clinical data
[n (%)]
Adverse events &
complications
[n (%)]
Resource
use
[n (%)]
Costs
[n (%)]
Utility
[n (%)]
Before 2009 H1N1
pandemic
Rank 1 2 (9) 0 (0) 0 (0) 0 (0) 1 (5) 0 (0)
Rank 2 2 (9) 2 (9) 1 (5) 5 (23) 9 (41) 1 (13)
Rank 3 5 (23) 1 (5) 4 (21) 1 (5) 3 (14) 1 (13)
Rank 4 2 (9) 3 (14) 2 (11) 0 (0) 2 (9) 2 (25)
Rank 5 0 (0) 7 (32) 5 (26) 6 (27) 0 (0) 2 (25)
Rank 6 6 (27) 6 (27) 4 (21) 6 (27) 7 (32) 2 (25)
Rank 9 5 (23) 3 (14) 3 (16) 4 (18) 0 (0) 0 (0)
Total 22 (100) 22 (100) 19 (100) 22 (100) 22 (100) 8 (100)
After 2009 H1N1
pandemic
Rank 1 1 (5) 1 (5) 0 (0) 3 (14) 1 (5) 1 (11)
Rank 2 3 (14) 9 (41) 1 (6) 7 (33) 11 (52) 0 (0)
Rank 3 4 (18) 1 (5) 0 (0) 1 (5) 2 (10) 4 (44)
Rank 4 4 (18) 2 (9) 2 (12) 2 (10) 0 (0) 4 (44)
Rank 5 0 (0) 3 (14) 5 (29) 3 (14) 3 (14) 0 (0)
Rank 6 7 (32) 4 (18) 3 (18) 3 (14) 2 (10) 0 (0)
Rank 9 3 (14) 2 (9) 6 (35) 2 (10) 2 (10) 0 (0)
Total 22 (100) 22 (100) 17 (100) 21 (100) 21 (100) 9 (100)
Note: For explanation about the ranking of each type of parameters refer to Table S3.
doi:10.1371/journal.pone.0030333.t004
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support countries to allocate resources such as the WHO, the
United Nations Children’s Fund (UNICEF), and the World Bank.
However, interpreting the results of Figure 3 needs to be done
with caution. This synthesis is dominated by only three studies,
although data from 16 out of 44 studies were used. This is
because the authors of these papers [29,40,46] assessed a wide
range of pharmaceutical and non-pharmaceutical interventions
and met the eligibility criterion to be included in the figure (i.e.,
presenting results in terms of incremental cost utility ratios)
(Table S8).
Apart from the recognized challenges of conducting systematic
reviews of economic evaluations, [55] we synthesized all studies
presenting cost utility ratios (shown in Figure 3) due to the paucity
of data, regardless of the quality of the evidence and methodology
used. However, this should not significantly affect our results, since
the overall quality of both input evidence and economic evaluation
methods is similar across the studies. In addition, despite our effort
to provide information on cost effective interventions for
developing countries by using the World Bank’s thresholds, the
transferability of cost outcomes across jurisdictions remains a
controversial issue. [56]
In comparison to the work of Lugne ´r and Postma, [57] who
reviewed economic evaluations of influenza pandemic interven-
tions from MEDLINE as their sole source, our review is more
comprehensive. Lugne ´r and Postma only provided descriptive
results of the review and methodological recommendations for
future economic evaluations. [57] Whilst our review does not focus
on examining methodological approaches but aims to offer policy
recommendations, it does not fully succeed due to the limitations
of the reviewed studies. These include the paucity of effectiveness
and cost effectiveness studies on non-pharmaceutical interventions,
and the limited number of studies assessing value for money across
interventions.
Moving forward
To strengthen the evidence base for preparedness strategies and
interventions against influenza pandemics, there are four major
recommendations. Firstly, research should be encouraged and
facilitated for both the effectiveness and cost effectiveness of
interventions against influenza pandemics, especially in developing
countries. In addition, new acceptable guidelines for the economic
evaluation of interventions should be developed to complement
the existing guidelines.
Secondly, we recommend that future economic evaluations
should apply a more transparent and systematic approach to
analyze uncertainty surrounding the input parameters. This can
be achieved by using the value of information approach, [58]
namely ‘expected value of perfect information for parameters’,
which is a technique to estimate the value of reducing the
uncertainty around particular parameters in the model. This
technique was very rarely used in our reviewed studies.
Figure 3. Incremental Cost Effectiveness Ratios (ICERs) for influenza pandemics according to type of intervention (I$/QALY).
AVP=antiviral prophylaxis; AVT=antiviral treatment; CJ=clinical judgment; PCR=polymerase chain reaction; PoC=point of care test; HR=high
risk for complications; LR=low risk for complications; VAC=vaccine; Blue=results of studies conducted before the 2009 H1N1 pandemic;
Green=results of studies conducted after the 2009 H1N1 pandemic; X=average incremental cost effectiveness ratio; ???=cost saving intervention,
ICER was not clearly stated; w=Cost saving/less effective intervention, ICER was not clearly stated.
doi:10.1371/journal.pone.0030333.g003
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the global community should be ready for the next event by
measuring the consequences of influenza pandemics and their
related interventions. Guidelines not only for the preparedness of
influenza pandemics, but also for assessing their impact in a
systematic and reliable manner are strongly warranted.
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